TY - JOUR
T1 - New drugs for tuberculosis treatment
AU - Sánchez, Francesca
AU - López Colomés, José L.
AU - Villarino, Elsa
AU - Grosset, Jacques
PY - 2011/3
Y1 - 2011/3
N2 - Available data on anti-tuberculosis drug research reveal different properties of the agents and provoke speculation about future directions. Higher doses of the rifamycins are promising and are currently being evaluated in regimens of shorter duration that the isoniazid plus rifampin-based, six-to-nine month-course therapy. Moxifloxacin and gatifloxacin might shorten tuberculosis treatment as well, possibly in combination with rifapentine, while SQ109 could enhance the activity of rifampin-containing regimens. On the other hand, co-administration of moxifloxacin and PA-824 could be active against latent tuberculosis, whereas linezolid, PA-824 and TMC207 are candidates for a rifampin-free regimen in multidrug-resistant and extensively-resistant tuberculosis. Unfortunately, shorter than existent treatment regimens based on the new agents discussed here are likely to take at least another decade to be fully developed and implemented in clinical practice.
AB - Available data on anti-tuberculosis drug research reveal different properties of the agents and provoke speculation about future directions. Higher doses of the rifamycins are promising and are currently being evaluated in regimens of shorter duration that the isoniazid plus rifampin-based, six-to-nine month-course therapy. Moxifloxacin and gatifloxacin might shorten tuberculosis treatment as well, possibly in combination with rifapentine, while SQ109 could enhance the activity of rifampin-containing regimens. On the other hand, co-administration of moxifloxacin and PA-824 could be active against latent tuberculosis, whereas linezolid, PA-824 and TMC207 are candidates for a rifampin-free regimen in multidrug-resistant and extensively-resistant tuberculosis. Unfortunately, shorter than existent treatment regimens based on the new agents discussed here are likely to take at least another decade to be fully developed and implemented in clinical practice.
KW - High dose of rifamycins
KW - New drug combinations
UR - http://www.scopus.com/inward/record.url?scp=79952958570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952958570&partnerID=8YFLogxK
U2 - 10.1016/S0213-005X(11)70018-0
DO - 10.1016/S0213-005X(11)70018-0
M3 - Article
C2 - 21420567
AN - SCOPUS:79952958570
SN - 0213-005X
VL - 29
SP - 47
EP - 56
JO - Enfermedades Infecciosas y Microbiologia Clinica
JF - Enfermedades Infecciosas y Microbiologia Clinica
IS - SUPPL. 1
ER -